Cayson Acquisition Quote - CAPN

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

10.00

Bid

9.78

Ask

15.90

Volume

0.00 Day's Range 0.00

0.70 52 Week Range 10.18

Market Cap

304.99M

Previous Close

10.00

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

23,733

Shares Outstanding

30,499,000

Dividend Yield

PE Ratio

-36.90

Earnings Per Share (EPS)

-1.28

Revenue

Net Profit

-38.99M

Sector

Electromedical Apparatus

Industry

Electromedical Apparatus

Website

www.capnia.com

Headquarters

Wilmington, Delaware, USA

Founded

Cayson Acquisition Corporation is listed in the Electromedical Apparatus sector of the NASDAQ with ticker CAPN. The last closing price for Cayson Acquisition was US$10. Over the last year, Cayson Acquisition shares have traded in a share price range of US$ 0.70 to US$ 10.18.

Cayson Acquisition currently has 30,499,000 shares outstanding. The market capitalization of Cayson Acquisition is US$304.99 million. Cayson Acquisition has a price to earnings ratio (PE ratio) of -36.90.

Cayson Acquisition Corp Announces Separate Trading of its Ordinary Shares and Rights

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cayson Acquisition Corp (NASDAQ:CAPNU) (the “Company”) announced today that, commencing on or about October 24, 2024, holders of its units sold in the...

Cayson Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cayson Acquisition Corp (the “Company”) announced today that it priced its initial public offering of 6,000,000 units at $10.00 per unit. The...

Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare, Inc.

REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome

Positive guidance received on key elements of Phase III programCompany expects to initiate pivotal Phase III clinical trial by year-end 2017DCCR has orphan designation for the treatment of PWS...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.02	0.200400801603	9.98	10	9.97	48138	9.99399609	CS
4	0.0095	0.095090335819	9.9905	10.005	9.97	21033	9.99300129	CS
12	9.3	1328.57142857	0.7	10.18	0.7	23733	9.97546087	CS
26	9.3	1328.57142857	0.7	10.18	0.7	11213	9.97546087	CS
52	9.3	1328.57142857	0.7	10.18	0.7	5651	9.97546087	CS
156	9.3	1328.57142857	0.7	10.18	0.7	1884	9.97546087	CS
260	9.3	1328.57142857	0.7	10.18	0.7	1351	9.97546087	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PALIPalisade Bio Inc	US$ 3.20 (128.57%)	20.1M
SYTASiyata Mobile Inc	US$ 1.05 (40.37%)	12.24M
TRVITrevi Therapeutics Inc	US$ 3.40 (36.55%)	2.47M
ZENAZenaTech Inc	US$ 7.46 (31.11%)	3.6M
ATLNAtlantic International Corporation	US$ 7.00 (22.74%)	1
KROSKeros Therapeutics Inc	US$ 18.78 (-72.64%)	609.66k
SPGCSacks Parente Golf Inc	US$ 0.50 (-64.29%)	163.73k
PNBKPatriot National Bancorp Inc	US$ 1.08 (-58.78%)	16
AVGRAvinger Inc	US$ 0.441 (-46.22%)	87.3k
HEPAHepion Pharmaceuticals Inc	US$ 0.36 (-38.46%)	1
PALIPalisade Bio Inc	US$ 3.20 (128.57%)	20.1M
CDTConduit Pharmaceuticals Inc	US$ 0.1012 (14.61%)	14.2M
AMPGAmplitech Group Inc	US$ 2.20 (13.99%)	13.48M
SYTASiyata Mobile Inc	US$ 1.05 (40.37%)	12.24M
LAESSEALSQ Corporation	US$ 1.245 (8.26%)	8.74M